Allergan Acquired “Anterios” developers of topical (Botox) botulinum toxin cream
We are pleased to announce the completion of Allergan acquisition of Anterios Inc., a privately-held biopharmaceutical company focused on developing topical botulinum toxin-based prescription products for medical dermatology and aesthetic medicine.
Allergan Inks $90 Million Deal for Anterios developers
Allergan says deal gives it access to new a drug delivery system
Allergan PLC, which last year agreed to merge with Pfizer Inc., on Thursday said it will buy clinical-stage pharmaceutical company Anterios Inc.
Under the terms of the deal, Allergan will pay Anterios $90 million up front, plus milestone payments.
Anterios is the developer of NDS, a technology that delivers neurotoxins through the skin instead of through injection. Allergan is perhaps best known as the maker of Botox, a neurotoxin with both cosmetic and therapeutic variations used to treat everything from wrinkles to osteoarthritis.
In a news release, Allergan Executive Vice President David Nicholson said the deal allows Allergan to advance “a new delivery system and formulations that are appealing to both patients and physicians.”
Additionally, Allergan has acquired the rights to Anterios’ Phase 2 program ANT-1207, a botulinum toxin topical lotion, for the treatment of hyperhidrosis, acne, and crow’s feet lines.
Allergan in November agreed to a more than $150 billion tie-up with Pfizer, a historic merger that would create the world’s biggest drugmaker. The combined company will have top-selling products including Pfizer’s Prevnar pneumonia vaccine and Allergan’s Botox, and an industry-topping R&D budget.